A Study of Linvoseltamab Versus Daratumumab in
People With Smoldering Multiple Myeloma at High Risk of Developing Multiple
Myeloma

Full Title

A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Carlyn Tan’s office at 646-608-3778.

Protocol
26-308
Phase
Phase III (phase 3)
Investigator
Carlyn Rose Tan
Co-Investigators
Saad Z. Usmani
Diseases
Hematology › Multiple Myeloma
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07393282
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description